Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05208762 · ClinicalTrials.gov registry record · Phase 1

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

A Phase 1 study of Endometrial Cancer and Gastric Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Recruiting
Registry status
Phase 1
Development phase
714
Enrollment target
20
Study locations

NCT05208762: Recruiting Phase 1 study of Endometrial Cancer and Gastric Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

NCT05208762 is a Phase 1 study of Endometrial Cancer and Gastric Cancer that is actively recruiting participants, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 714 participants, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05208762, a Phase 1 study of Endometrial Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
714 participants
Enrollment target
20
Study locations

Study Summary

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.

Primary Outcome

Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

Conditions Studied

Endometrial Cancer Gastric Cancer Hepatocellular Carcinoma Carcinoma, Non-Small Cell Lung Pancreatic Adenocarcinoma Squamous Cell Carcinoma of the Head and Neck Esophageal Squamous Cell Carcinoma Triple Negative Breast Neoplasms

Interventions

  • DRUG pembrolizumab
  • DRUG PF-08046054

Study Locations (20)

Texas

  • University of Texas Southwestern Medical Center - Simmons Cancer Center - Dallas
  • UT Southwestern Medical Center - Redbird - Dallas
  • Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital - Dallas
  • University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital - Dallas
  • University Of Texas Southwestern Medical Center - Dallas
  • UT Southwestern - Simmons Cancer Center - Fort Worth - Fort Worth
  • The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services - Houston
  • The University of Texas MD Anderson Cancer Center - Houston

Alabama

  • University of Alabama at Birmingham - Birmingham
  • University of Alabama at Birmingham, IDS Pharmacy - Birmingham
  • University of Alabama at Birmingham - Birmingham
  • University of Alabama at Birmingham - Birmingham

California

  • Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
  • UC Irvine Health - Chao Family Comprehensive Cancer Center - Orange
  • University of California Davis Comprehensive Cancer Center - Sacramento
  • University of California, Davis Medical Center - Sacramento

Michigan

  • Karmanos Cancer Institute - Detroit
  • Karmanos Cancer Institute - Farmington Hills

Iowa

  • University of Iowa - Iowa City

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Trial Details

FieldValue
Enrollment Target 714 participants
Start Date 2022-10-25
Est. Completion 2029-01-04
Phase Phase 1
Seagen, a wholly owned subsidiary of Pfizer

28 total trials

What NCT05208762 shows while recruiting

NCT05208762 is an interventional study that assigns participants to a tested intervention. The registered 714 participants enrollment target is mid-sized for trials with a published cap, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher).

The record links to 8 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.

NCT05208762 names 20 study sites across 6 states, led by Texas, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT05208762 about?

NCT05208762 is a clinical study titled "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors". This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum...

What is the current status of trial NCT05208762?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 714 participants. The study started on 2022-10-25. Estimated completion is 2029-01-04.

What conditions does trial NCT05208762 study?

This clinical trial studies the following conditions: Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Carcinoma, Non-Small Cell Lung, Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT05208762?

The interventions under investigation include: pembrolizumab (DRUG), PF-08046054 (DRUG).

Who is sponsoring clinical trial NCT05208762?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05208762 being conducted?

This trial has 20 study locations across Alabama, California, Iowa, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05208762's enrollment target sits among peer trials

714 19th of 181 higher than 163 of 181 other Endometrial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06758401 · 714 participants · Phase 3

    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • NCT04680000 · 716 participants · NA

    Chronic Pain Management In Primary Care Using Behavioral Health Consultants

  • NCT06179160 · 710 participants · Phase 1

    A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  • NCT06235697 · 710 participants · Phase 3

    Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05208762

Source: ClinicalTrials.gov NCT05208762, the US trial registry maintained by the National Library of Medicine. NCT05208762 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.